Bioactivity:

Linaclotide�developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, and is a potent and selective guanylate cyclase C agonist.

CAS nr:

851199-59-2

Purity:

98%

Molecular Weight:

1526,74

SMILES:

O=C([C@@H](NC([C@@](CSSC[C@@H]1N)([H])NC([C@@](CSSC[C@H](N2)C(N[C@H](C(O)=O)CC3=CC=C(O)C=C3)=O)([H])NC([C@@H](NC([C@@H](N4)CCC(O)=O)=O)CC5=CC=C(O)C=C5)=O)=O)=O)CC(N)=O)N6[C@@](C(N[C@H](C(N[C@](CSSC[C@](C4=O)([H])NC1=O)([H])C(NC(C(NCC2=O)=O)[C@H](O)C)=O)=O)C)=O)([H])CCC6

Formula:

C59H79N15O21S6

Pathway:

GPCR/G Protein

Target:

Guanylate cyclase